Sonia Samtani
Interventional Cardiology · Clinton, MDNPI 1548526080
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,197 of the $17,134 with a category attached, or 65.3%. 37 manufacturers reported payments, led by Medtronic at 25.3% of the total.
Across 248 payments — averaging $69.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Abbott$3K
- Atricure, Inc.$1K
- Teleflex LLC$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$763
- Amgen$709
- plus $6K from 31 others
What the payments were for
- Travel & lodging$5,75134%
- Food & beverage$11,19765%
- Education$1861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 67 | $4,332 |
| Abbott | 24 | $2,941 |
| Atricure, Inc. | 5 | $1,495 |
| Teleflex LLC | 8 | $1,143 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $763 |
| Amgen | 26 | $709 |
| Edwards Lifesciences | 15 | $665 |
| Boston Scientific | 9 | $595 |
| Abiomed | 5 | $521 |
| Asahi Intecc USA, Inc. | 13 | $482 |
| Cardiovascular Systems Inc. | 3 | $346 |
| AstraZeneca | 6 | $298 |
| Akcea Therapeutics, Inc. | 8 | $286 |
| Philips North America LLC | 3 | $260 |
| E.r. Squibb & Sons, L.L.C. | 4 | $232 |
| Impulse Dynamics (USA) Inc. | 1 | $228 |
| Cvrx, Inc. | 1 | $208 |
| Merck | 5 | $202 |
| Johnson & Johnson | 5 | $194 |
| Verge Medical, Inc. | 2 | $182 |
| Actelion Pharmaceuticals US, Inc. | 2 | $144 |
| Penumbra, Inc. | 1 | $137 |
| Esperion Therapeutics, Inc. | 1 | $122 |
| Novartis | 6 | $105 |
| GSK | 1 | $76 |
| Cook Medical LLC | 2 | $73 |
| Terumo Medical Corporation | 3 | $67 |
| Kestra Medical Technology Services, Inc. | 1 | $62 |
| Shockwave Medical, Inc | 2 | $60 |
| Novo Nordisk | 1 | $50 |
| Scpharmaceuticals Inc. | 1 | $28 |
| Cagent Vascular Inc | 1 | $24 |
| Boehringer Ingelheim | 1 | $24 |
| Pfizer | 1 | $21 |
| Cordis US CORP. | 1 | $20 |
| W. L. Gore & Associates, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$1,344
- ONYX FRONTIER$1,030
- GUIDELINER$985
- RESOLUTE ONYX$869
- OPTIS$688
- SYMPLICITY G3$391
- Impella$381
- LifeVest$341
- ACCOLADE SR$303
- Edwards SAPIEN 3 Transcatheter Heart Valve$284
- Xience V coronary stent system$257
- COREVALVE EVOLUT R$256
- VERQUVO$250
- OPTIMIZER$228
- Coronary Orbital Atherectomy System$224
- Barostim Neo System$208
- Micra$193
- DRAGONFLY OPSTAR$179
- OMNILINK ELITE$167
- JOT DX$164
How this compares
$17,134 in reported general payments places this provider in the 70th percentile of 71 interventional cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 138 | $199,088 |
| XareltoRivaroxaban | 40 | $52,950 |
| EntrestoSacubitril/Valsartan | 28 | $33,261 |
| Repatha SureclickEvolocumab | 28 | $33,054 |
| BrilintaTicagrelor | 26 | $25,752 |
| JardianceEmpagliflozin | 19 | $21,201 |
| OzempicSemaglutide | 12 | $7,837 |
| Metoprolol Succinate | 424 | $7,530 |
| Rosuvastatin Calcium | 209 | $4,872 |
| EdarbiAzilsartan Medoxomil | 14 | $4,057 |
| Candesartan Cilexetil | 22 | $3,428 |
| Atorvastatin Calcium | 345 | $3,420 |
| Clonidine | 11 | $3,003 |
| ClopidogrelClopidogrel Bisulfate | 162 | $2,265 |
| Nifedipine ErNifedipine | 96 | $2,163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $21 | $199,088138 claims |
| Johnson & JohnsonXarelto | $194 | $52,95040 claims |
| NovartisEntresto | $105 | $33,26128 claims |
| AstraZenecaBrilinta | $298 | $25,75226 claims |
| Boehringer IngelheimJardiance | $24 | $21,20119 claims |
| Novo NordiskOzempic | $50 | $7,83712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 71 interventional cardiology providers in Maryland.
Other interventional cardiology in Clinton
- Rimmy FarrakhanClinton$5K
- Vinay SatwahGreenbelt$679K
- Aloke FinnBaltimore$575K
- Michael ChenRockville$241K
- John WangBaltimore$138K
- Steven HearneSalisbury$100K
- Amir NajafiBel Air$82K
- Diljon ChahalBaltimore$78K
- Joseph CinderellaSalisbury$72K
- Ali TabrizchiBel Air$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.